Comparing Injection Site Reactions of Aprepitant and Fosaprepitant in Gynecologic Cancer Chemotherapy.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2024-09-01 DOI:10.21873/invivo.13704

Seira Nishibe-Toyosato, Yosuke Ando, Yutaka Torii, Ryoko Ichikawa, Akiko Owaki, Hironori Miyamura, Eiji Nishio, Hidezo Matsuda, Naho Tsujii-Fujii, Akane Shimato-Isobe, Kotone Mukaiji, Kaori Ito, Takahiro Hayashi, Takuma Fujii, Shigeki Yamada

{"title":"Comparing Injection Site Reactions of Aprepitant and Fosaprepitant in Gynecologic Cancer Chemotherapy.","authors":"Seira Nishibe-Toyosato, Yosuke Ando, Yutaka Torii, Ryoko Ichikawa, Akiko Owaki, Hironori Miyamura, Eiji Nishio, Hidezo Matsuda, Naho Tsujii-Fujii, Akane Shimato-Isobe, Kotone Mukaiji, Kaori Ito, Takahiro Hayashi, Takuma Fujii, Shigeki Yamada","doi":"10.21873/invivo.13704","DOIUrl":null,"url":null,"abstract":"Background/aim: The frequency rate of injection site reactions (ISR) due to fosaprepitant meglumine (Fos APR) has been shown to vary depending on the types of combined anticancer drug. This study aimed to elucidate the impact of Fos APR on ISR in patients receiving paclitaxel and carboplatin, with and without bevacizumab therapy (TC±Bev).Patients and methods: This study focused on patients with gynecologic cancer (n=93) who received TC±Bev administration at Fujita Health University Hospital from March 2016 to February 2020, and monitored up to six cycles. The patients were randomly assigned to the Fos APR group (n=47) and the Aprepitant (APR) group (n=46). Using Visual Infusion Phlebitis (VIP) scores, ISR was evaluated by comparing the VIP scores of all cycles using a linear mixed model. The risk factors that contribute to the occurrence of vascular pain throughout all cycles were also examined.Results: The VIP scores of all cycles showed a near significant intergroup difference (p=0.071). Factors that affected the development of vascular pain included Fos APR and age (p=0.027 and 0.049, respectively). Regarding age, patients aged <65 years had a higher risk. Four patients underwent a switch from the originally assigned neurokinin-1 receptor antagonist; in all of these cases, Fos APR was changed to APR for vascular pain.Conclusion: Fos APR may increase the risk for ISR associated with TC±Bev therapy for gynecological cancer.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11363802/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13704","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The frequency rate of injection site reactions (ISR) due to fosaprepitant meglumine (Fos APR) has been shown to vary depending on the types of combined anticancer drug. This study aimed to elucidate the impact of Fos APR on ISR in patients receiving paclitaxel and carboplatin, with and without bevacizumab therapy (TC±Bev).

Patients and methods: This study focused on patients with gynecologic cancer (n=93) who received TC±Bev administration at Fujita Health University Hospital from March 2016 to February 2020, and monitored up to six cycles. The patients were randomly assigned to the Fos APR group (n=47) and the Aprepitant (APR) group (n=46). Using Visual Infusion Phlebitis (VIP) scores, ISR was evaluated by comparing the VIP scores of all cycles using a linear mixed model. The risk factors that contribute to the occurrence of vascular pain throughout all cycles were also examined.

Results: The VIP scores of all cycles showed a near significant intergroup difference (p=0.071). Factors that affected the development of vascular pain included Fos APR and age (p=0.027 and 0.049, respectively). Regarding age, patients aged <65 years had a higher risk. Four patients underwent a switch from the originally assigned neurokinin-1 receptor antagonist; in all of these cases, Fos APR was changed to APR for vascular pain.

Conclusion: Fos APR may increase the risk for ISR associated with TC±Bev therapy for gynecological cancer.

查看原文本刊更多论文

比较阿瑞匹坦和福沙匹坦在妇科癌症化疗中的注射部位反应

背景/目的：研究表明，福沙匹坦葡甲胺（Fos APR）引起的注射部位反应（ISR）的发生率因联合抗癌药物的类型而异。本研究旨在阐明 Fos APR 对接受紫杉醇和卡铂治疗及未接受贝伐单抗治疗（TC±Bev）患者 ISR 的影响：本研究主要针对2016年3月至2020年2月期间在富士田保健大学医院接受TC±Bev治疗的妇科癌症患者（n=93），并对其进行了长达6个周期的监测。患者被随机分配到 Fos APR 组（n=47）和 Aprepitant (APR) 组（n=46）。使用可视输液静脉炎（VIP）评分，通过线性混合模型比较所有周期的VIP评分来评估ISR。此外，还研究了导致所有周期发生血管疼痛的风险因素：结果：所有周期的 VIP 评分均显示出近乎显著的组间差异（P=0.071）。影响血管痛发生的因素包括 Fos APR 和年龄（分别为 p=0.027 和 0.049）。结论Fos APR 可能会增加与 TC±Bev 治疗妇科癌症相关的 ISR 风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.